Researchers have identified 2 new prognostic factors for survival among patients requiring second-line targeted therapy for metastatic renal cell carcinoma (mRCC), according to a report presented at the 2015 European Cancer Congress.
In a retrospective study of 316 mRCC patients who received second-line targeted therapy, Lisa Derosa, MD, and colleagues at Institute Gustave Roussy in Villejuif, France, found that tumor burden and time from first- to second-line treatment independently predicted mortality risk. Each 10 mm increment in tumor burden prior to second-line therapy was associated with a significant 2.6% increased risk of death, and a 6–12 month and greater than 12 month interval between first- and second-line therapy were associated with a 47% and 20% decreased risk, respectively, compared with an interval of less than 6 months.
The Institute Gustave Roussy team added these 2 factors to other known prognostic factors (except for hypercalcemia) used in existing predictive models (Memorial Sloan-Kettering Cancer Center [MSKCC] and International Metastatic Renal Cell Carcinoma Consortium [IMDC]) to create a new model consisting of 7 factors. This new model provides improved prognostic performance over the MSKCC and IMDC models, the researchers concluded.
The median follow-up of the 316 patients in the new study was 49.4 months; the median overall survival was 16.8 months.